5α‐reductase type 3 enzyme in benign and malignant prostate

Currently available 5α‐reductase inhibitors are not completely effective for treatment of benign prostate enlargement, prevention of prostate cancer (CaP), or treatment of advanced castration‐recurrent (CR) CaP. We tested the hypothesis that a novel 5α‐reductase, 5α‐reductase‐3, contributes to residual androgen metabolism, especially in CR‐CaP.

[1]  C. Sander,et al.  Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. , 2012, Cancer research.

[2]  M. Dowsett,et al.  Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. , 2012, The Journal of clinical endocrinology and metabolism.

[3]  Rui Li,et al.  Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[4]  J. Mohler,et al.  5α‐reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression , 2011, The Prostate.

[5]  J. Mohler,et al.  Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone , 2011, Clinical Cancer Research.

[6]  H. Freeze,et al.  SRD5A3 Is Required for Converting Polyprenol to Dolichol and Is Mutated in a Congenital Glycosylation Disorder , 2010, Cell.

[7]  K. Tomer,et al.  Atmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer. , 2010, Analytical chemistry.

[8]  Dan S. Tawfik,et al.  Enzyme promiscuity: a mechanistic and evolutionary perspective. , 2010, Annual review of biochemistry.

[9]  V. Langlois,et al.  Evolution of steroid-5alpha-reductases and comparison of their function with 5beta-reductase. , 2010, General and comparative endocrinology.

[10]  P. Walsh,et al.  Chemoprevention of prostate cancer. , 2010, The New England journal of medicine.

[11]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[12]  Melani-Ivy Samson,et al.  Sequential transformation of 4-androstenedione into dihydrotestosterone in prostate carcinoma (DU-145) cells indicates that 4-androstenedione and not testosterone is the substrate of 5α-reductase , 2010, Hormone molecular biology and clinical investigation.

[13]  D. Tindall,et al.  Effects of the 5 alpha‐reductase inhibitor dutasteride on gene expression in prostate cancer xenografts , 2009, The Prostate.

[14]  C. Morrison,et al.  Central quadrant procurement of radical prostatectomy specimens , 2009, The Prostate.

[15]  G. Wilding,et al.  Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. , 2009, The Journal of urology.

[16]  R. Rittmaster,et al.  Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. , 2008, Urology.

[17]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[18]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[19]  Yusuke Nakamura,et al.  Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. , 2008, Cancer science.

[20]  Yusuke Nakamura,et al.  Novel 5α‐steroid reductase (SRD5A3, type‐3) is overexpressed in hormone‐refractory prostate cancer , 2007 .

[21]  R. Rittmaster,et al.  The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia , 2007, Prostate Cancer and Prostatic Diseases.

[22]  J. Isaacs,et al.  Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers , 2006, Clinical Cancer Research.

[23]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[24]  S. Frye.  Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. , 2006, Current topics in medicinal chemistry.

[25]  D. Peehl,et al.  Identification of the Major Oxidative 3α-Hydroxysteroid Dehydrogenase in Human Prostate That Converts 5α-Androstane-3α,17β-diol to 5α-Dihydrotestosterone: A Potential Therapeutic Target for Androgen-Dependent Disease , 2006 .

[26]  D. Peehl,et al.  Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. , 2006, Molecular endocrinology.

[27]  K. Tomer,et al.  Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[28]  M. Schell,et al.  Steroid 5α-Reductase Isozymes I and II in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[29]  D. Troyer,et al.  Differential alterations in 5α‐reductase type 1 and type 2 levels during development and progression of prostate cancer , 2005 .

[30]  M. Schell,et al.  Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  D. Troyer,et al.  Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. , 2005, The Prostate.

[32]  R. Auchus.  The backdoor pathway to dihydrotestosterone , 2004, Trends in Endocrinology & Metabolism.

[33]  D. Tindall,et al.  Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. , 2004, The Journal of urology.

[34]  M. Gleave,et al.  Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer , 2004 .

[35]  G. Cunningham,et al.  Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. , 2004, The Journal of clinical endocrinology and metabolism.

[36]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[37]  M. Carducci,et al.  Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. , 2004, Urology.

[38]  R. Auchus,et al.  5α-reduced C21 steroids are substrates for human cytochrome P450c17 , 2003 .

[39]  Jun Luo,et al.  Decreased gene expression of steroid 5 alpha‐reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma , 2003, The Prostate.

[40]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[41]  R. Auchus,et al.  5alpha-reduced C21 steroids are substrates for human cytochrome P450c17. , 2003, Archives of biochemistry and biophysics.

[42]  Jean D. Wilson.  The role of 5a-reduction in steroid hormone physiology , 2001 .

[43]  D. Russell,et al.  Unexpected Virilization in Male Mice Lacking Steroid 5α-Reductase Enzymes. , 2001, Endocrinology.

[44]  D. Russell,et al.  Unexpected virilization in male mice lacking steroid 5 alpha-reductase enzymes. , 2001, Endocrinology.

[45]  J. Wilson.  The role of 5alpha-reduction in steroid hormone physiology. , 2001, Reproduction, fertility, and development.

[46]  Michael E. Burczynski,et al.  Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1–AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones , 2000 .

[47]  N. Palackal,et al.  Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. , 2000, The Biochemical journal.

[48]  E. Fearon,et al.  Cancer progression , 1999, Current Biology.

[49]  D. Poirier,et al.  Separation by thin-layer chromatography of the most common androgen-derived C19 steroids formed by mammalian cells☆ , 1999, Steroids.

[50]  P. Span,et al.  Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. , 1999, The Journal of urology.

[51]  M. Poutanen,et al.  Characterization of 17B‐hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate , 1996 .

[52]  M. Poutanen,et al.  Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate. , 1996, International journal of cancer.

[53]  S. Frye,et al.  Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. , 1995, Biochemistry.

[54]  G. Andriole,et al.  Treatment with finasteride following radical prostatectomy for prostate cancer. , 1995, Urology.

[55]  J. D. Stuart,et al.  17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1. , 1994, Biochemistry.

[56]  D. Russell,et al.  Characterization of Chinese hamster ovary cell lines expressing human steroid 5 alpha-reductase isozymes. , 1993, The Journal of biological chemistry.

[57]  J. Isaacs,et al.  Response of rat and human prostatic cancers to the novel 5α‐reductase inhibitor, SK&F 105657 , 1992 .

[58]  J. Isaacs,et al.  Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. , 1992, The Prostate.

[59]  J. Epstein.  Evaluation of Radical Prostatectomy Capsular Margins of Resection: The Significance of Margins Designated as Negative, Closely Approaching, and Positive , 1990, The American journal of surgical pathology.

[60]  D. Thompson,et al.  Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. , 1990, The Journal of clinical endocrinology and metabolism.

[61]  M. Brandt,et al.  Mechanistic studies with solubilized rat liver steroid 5 alpha-reductase: elucidation of the kinetic mechanism. , 1990, Biochemistry.

[62]  K. Roberts,et al.  Steroidal inhibitors of prostatic 5α-reductase: Structure-activity relationships , 1978 .